Pfizer for Professionals logo

Health Care Professionals Log In

This site is intended for U.S. Health Care Professionals.

Our products are indicated for a wide range of tumor types. Click on the product link to see more information on safety, efficacy, dosing, and full prescribing information. Please see Important Safety Information below.

BOSULIF® (bosutinib) is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.

View: BOSULIF | Prescribing information

INLYTA® (axitinib) is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

View: INLYTA | Prescribing information

SUTENT® (sunitinib malate) is indicated for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, and progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.

View: SUTENT | Prescribing Information, including Boxed Warning and
Medication Guide
TORISEL® (temsirolimus) is indicated for the treatment of advanced renal cell carcinoma.

View: TORISEL | Prescribing information
XALKORI® (crizotinib) is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
This indication is based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.

View: XALKORI | Prescribing information